secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tarsus Pharmaceuticals, Inc. (TARS)
CIK:        0001819790
Form:       8-K
Filed at:   2025-02-25T23:59:59+00:00
Accession:  0001819790-25-000007
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tarsus Q4 XDEMVY sales $66.4M; full-year $180.1M; net loss narrows to $0.60/share
--------------------------------------------------------------------------------

- Q4 net product sales $66.4M (vs $13.1M YoY); full-year $180.1M (vs $14.7M), with 163,000 bottles dispensed in 2024.
- Net loss $23.1M ($0.60/share) in Q4 vs $41.9M ($1.31) in Q4 2023; full-year loss $115.6M ($3.07) vs $135.9M ($4.62).
- Cash and marketable securities $291.4M as of Dec 31, 2024; gross-to-net discount ~45% on XDEMVY.
- Pipeline: TP-04 for ocular rosacea on track to start Phase 2 in H2 2025; TP-05 for Lyme disease Phase 2 study planned.
- Appointed Dr. Elizabeth Yeu as CMO and Dr. Katherine Goodrich to Board of Directors.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1819790/000181979025000007/0001819790-25-000007-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1819790/000181979025000007/tars-20250225.htm
  HTML page:      https://secwatch.observer/filing/0001819790-25-000007

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer